Abstract: Cloning and expression of DNA segments encoding bovine IL-1.alpha., and processes for producing purified bovine IL-1.alpha. as a product of recombinant cell culture, are disclosed.

Abstract: Peptides or proteins related to a melanoma associated antigen are described. These are produced in large quantities via recombinant DNA techniques and/or by chemical synthetic methods. The peptides or proteins can be used as immunogens in vaccine formulations which can induce an immune response that selectively destroys melanoma cells in a vaccinated individual. Where the peptides or proteins are expressed by a recombinant virus, inactivated or live virus vaccine formulations may be prepared.

Abstract: Disclosed are a transformed mammalian cell that produces biologically active Protein S, and a vector for effecting the transformation of the cell. produces biologically active human Protein S, and the vector used to effect the transgenesis of the cell. The vector disclosed includes DNA encoding mature human Protein S, under the transcriptional control of a eukaryotic metallothionein gene, and also includes the transforming region of the bovine papilloma virus genome, and a fragment of SV40 DNA.

Abstract: The present invention provides for a plasmid, pEAP7.DELTA.P, containing a DNA region capable of inducing extracellular secretion of a useful, physiologically active substance in transformed host and a promoter DNA region regulating expression of the first DNA region. The present invention further provides for a microorganism transformed with the plasmid and a process for the production of the substances by culturing the microorganism.

Abstract: The present invention provides polypeptides having an amino acid sequence derived from the 190 kD precursor to the major merozoite surface antigens of the K1 isolate of Plasmodium falciparum. These polypeptides are capable of eliciting an immune response against different isolates of Plasmodium falciparum. The invention further provides immunogenic compositions and vaccines containing such polypeptides, antibodies raised against the polypeptides. a DNA sequence coding for one of the polypeptides, a replicable microbial vector containing such a DNA sequence and a microorganism transformed with such a vector. The invention also provides processes for the production of the polypeptides, immunogenic compositions, microorganisms and antibodies of the invention and for the use of the polypeptides and immunogenic compositions for the immunization of mammals against malaria.

Abstract: cDNA clones coding for TGF-.beta.2 which are used to construct expression vectors capable of directing the high-level expression of mature, biologically active TGF-.beta.2, as well as precursor TGF-.beta.2 forms, in transfected Chinese Hamster Ovary cells (CHO cells) and transfected COS cells are described. CHO and COS transfectants secreting TGF-.beta.2 at high levels are also described. CHO cells transfected with a plasmid vector carrying the complete 414 amino acid simian TGF-.beta.2 precursor secrete approximately 5 .mu.g per ml culture media.

Abstract: By screening an animal cell transformant, which has been obtained by introducing into wild-type animal cells a wild-type DHFR gene and a structural gene which codes a desired useful substance, with a medium containing methotrexate (MTX) at a concentration of 50 .mu.M or lower, both genes can be amplified effectively within an MTX resistant strain and a stable amplified transformant can also be obtained. The screening may be repeated using an increasing concentration of MTX. It is also possible to obtain stably the desired foreign gene product in a high yield by using the thus-obtained amplified transformant.

Abstract: The present invention relates to transmission-blocking vaccines against malaria. Vaccines of the present invention contain a recombinant Pfs25 Plasmodium falciparum protein produced by yeast cells and to yeast cells producing the protein. Mice and monkeys inoculated with the yeast-expressed Pfs25 of the present invention have developed antibodies with transmission-blocking activity. The present invention also relates to methods of preventing or treating malarial infections using the vaccines of the present invention.

Abstract: Genetic material encoding the P22 peptide of Toxoplasma gondii has been isolated and characterized. This genetic material allows the production of peptides for use in diagnosis or immunization or can itself be directly used in hybridization assays.

Abstract: This invention relates to a gene which codes for the IL-6 gene expression inducing nuclear factor C/EBP2 capable of binding sequence-specifically to the palindrome structure SEQ ID NO:2 located in the transcriptional regulatory region of the IL-6 gene; an expression plasmid with the C/EBP2 gene incorporated therein; an transformant harboring the expression plasmid; a recombinant C/EBP2 obtained by expressing the C/EBP2 gene; and a method of producing the recombinant C/EBP2.

Abstract: Novel vectors are provided for identifying secretory signal sequences from DNA fragments of unicellular microorganisms. The plasmids comprise a multiple cloning site with restriction sites in reading frame with a structural gene which permits rapid screening of the secreted expression product. Optionally, the vectors may include a promoter region upstream from the multiple cloning site. The invention is exemplified with Bacillus. Specific secretory signal sequences have been isolated with those vectors, allowing for efficient secretion into the supernatant, and not just to the periplasmic space to provide proteins in economically high yields. Secretory sequences are provided superior to other previously known sequences.

Abstract: Human pancreatic elastase can now be obtained from a genetically engineered source.

Abstract: Disclosed are DNA sequences encoding novel DNA binding proteins implicated in regulation of early stages of cell growth. Illustratively provided are human and mouse origin DNA sequences encoding early growth regulatory ("Egr") proteins which include "zinc finger" regions of the type involved in DNA binding. Also disclosed are immunological methods and materials for detection of Egr proteins and hybridization methods and materials for detection and quantification of Egr protein related nucleic acids.

Abstract: The present invention relates to a method for the stabilization of a plasmid vector contained in a bacterium, wherein the bacterium comprises a dap.sup.- chromosomal mutation and wherein the plasmid vector carries a dap.sup.+ gene.

Abstract: SPONSORSHIPThe invention described herein was supported by a grant from the Medical Research Council of Canada, grants from the National Institutes of Health and a grant from the Ajinomoto Corporation.

Abstract: A DNA molecule is provided which comprises a nucleotide sequence substantially corresponding to all or a portion of the base sequence coding for the mitochondrial autoantigen of primary biliary cirrhosis. This DNA molecule may be linked to an expression control sequence. A synthetic peptide or polypeptide is provided which includes at least an amino acid sequence substantially as shown in FIG. 6 or FIG. 8. This synthetic peptide or polypeptide may be prepared by expression of a host cell which has been transformed with a recombinant DNA molecule as described above, or by chemical synthesis.

Abstract: Purified BMP-6 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.

Abstract: Nucleic acid molecules are provided which encode antigenic proteins capable of inducing in a chicken an immune response conferring protection against Eimeria tenella. Expression vectors containing the nucleic acid molecules are also provided. Methods for producing the proteins or antigenic polypeptides having amino acid sequences included within these proteins are also provided.

Abstract: The subject invention concerns the identification of novel merozoite surface proteins of Babesia bovis. Also disclosed are monoclonal antibodies to these proteins as well as genes which encode for the proteins.The invention further concerns the use of the novel proteins, recombinant DNA clones, and monoclonal antibodies in the detection, treatment, and prophylaxis of babesiosis.

Abstract: Disclosed and claimed are toluene monooxygenase (TMO) gene sequences from Pseudomonas mendocina KR-1, TMO proteins encoded by these sequences, recombinant plasmids containing such sequences, and microorganism host cells containing such plasmids. A five-gene and six-gene TMO gene cluster encode proteins that are useful in a variety of bioconversions. In particular, the TMO gene cluster is useful for the preparation of p-hydroxyphenylacetic acid and indigo. In addition, the TMO gene cluster is useful for the degradative bioconversion of toxic compounds, such as trichloroethylene.